Top Story Today
AstraZeneca Slides $2 Billion Across the Table to Summit Therapeutics. No Strings Attached.
AstraZeneca invested $2 billion in Summit Therapeutics for roughly 12% ownership, with no royalties, no milestones, and no profit-sharing. The target: ivonescimab, a bispecific antibody that blocks two cancer pathways simultaneously and has posted results in three Phase 3 trials so far. The plan is to combine ivonescimab with AstraZeneca's antibody-drug conjugates, starting in GI cancers. Summit's stock surged, but the drug still needs FDA approval (decision date: November 14, 2026), and one key survival endpoint just missed statistical significance.
Why it matters: A $2 billion no-strings commitment to a single partner signals that Big Pharma sees combination immunotherapy as the next frontier in oncology, and it's willing to pay for optionality before the science is even finished.
Read more →Deals and Strategy
Novo Nordisk's $1.4 Billion Bet That Pills Can Replace Needles
Novo Nordisk signed a deal worth up to $1.4 billion with Copenhagen-based Orbis Medicines to develop oral cardiometabolic therapies using synthetic macrocycles, molecules that hit biologic-level targets but can be swallowed as a pill. It's one piece of a multi-billion-dollar shopping spree as Novo races to convert the injectable GLP-1 empire into an oral business before Eli Lilly and AstraZeneca beat them to it.
Read more →Novartis Killed a Trial of Its Own Blockbuster Drug. The Reason? 'Strategy.'
Novartis terminated a mid-stage Fabhalta trial in lupus nephritis after completing Part 1, citing only "strategic considerations." No safety issue, no efficacy failure. The drug already has three approvals, $505 million in 2025 sales, and according to Novartis, $3 billion or more in peak potential. The likely read: Novartis decided the complement drug's strongest hands are in existing kidney indications, not the notoriously difficult lupus space.
Read more →Clinical and Regulatory
The FDA Approved a Drug That Failed One of Its Own Pivotal Trials
Roche's Enspryng won FDA approval for thyroid eye disease despite one of its two pivotal trials missing statistical significance. The second trial cleared convincingly, and the agency cited the "totality of evidence." It becomes the first at-home injectable for TED, giving patients a convenient alternative to Tepezza's infusion-center visits.
Read more →Uncle Sam Wants AI to Run Your Clinical Trials
HHS launched four AI programs through ARPA-H to overhaul clinical trials: SURPASS simulates trials before they start; STACK activates new trial sites using AI; COMMONS builds national research data infrastructure; and CINCH matches cancer patients with studies. Industry estimates suggest AI could cut drug development timelines by 30 to 50%, though skeptics note the operational reality lags far behind the technology.
Read more →Funding and Launches
A Nobel Laureate's CRISPR Biotech Just Ran Out of Road
Caribou Biosciences, co-founded by Nobel laureate Jennifer Doudna, is winding down its CAR-T pipeline, cutting most staff, and exploring strategic alternatives after failing to raise the capital needed for later-stage trials. Its gene-edited CAR-T therapy showed an 82% response rate in one study, but $596.5 million in accumulated losses and a hostile funding environment proved fatal. The wind-down caps a brutal stretch for CRISPR companies, with layoffs and shutdowns across the sector throughout 2025 and 2026.
Read more →$103 Million to Fix the Gene Behind 1-in-1,000 Kidney Disease
Estuary Biotherapeutics emerged from stealth with $103 million to develop gene therapies for ADPKD, the most common inherited kidney disease. Built on Yale research showing that restoring polycystin proteins can actually reverse cyst formation in mice, the company plans two programs targeting both major disease-causing genes, with clinic entry expected in 2027.
Read more →Biotech's IPO Drought Is Officially Over
After a prolonged drought where the entire IPO class could fit in a minivan, 22 biotech companies have gone public in 2026, raising $6.9 billion through September and delivering 42% average returns. This week's additions: AI drug discovery company Iambic Therapeutics ($150M raise, Nvidia-backed) and RNAi player City Therapeutics ($200M). The window is open, but rising bond yields could narrow it fast.
Read more →